These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 35924783)

  • 1. On what basis did Health Canada approve OxyContin in 1996? A retrospective analysis of regulatory data.
    Pappin J; Bavli I; Herder M
    Clin Trials; 2022 Oct; 19(5):584-590. PubMed ID: 35924783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ORIGINS OF THE OPIOID CRISIS AND ITS ENDURING IMPACTS.
    Alpert A; Evans WN; Lieber EMJ; Powell D
    Q J Econ; 2022 May; 137(2):1139-1179. PubMed ID: 35832727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The marketing of OxyContin®: A cautionary tale.
    Egilman DS; Collins GDYCB; Falender J; Shembo N; Keegan C; Tohan S
    Indian J Med Ethics; 2019; 4(3):183-193. PubMed ID: 31727614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Representations of OxyContin in North American newspapers and medical journals.
    Whelan E; Asbridge M; Haydt S
    Pain Res Manag; 2011; 16(4):252-8. PubMed ID: 22059195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004.
    Cicero TJ; Inciardi JA; Muñoz A
    J Pain; 2005 Oct; 6(10):662-72. PubMed ID: 16202959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Industry influence and Health Canada's responsibility: lessons from the opioid epidemic in Canada.
    Bavli I
    Addiction; 2020 Sep; 115(9):1605-1606. PubMed ID: 31845436
    [No Abstract]   [Full Text] [Related]  

  • 7. OxyContin abuse and overdose.
    Aquina CT; Marques-Baptista A; Bridgeman P; Merlin MA
    Postgrad Med; 2009 Mar; 121(2):163-7. PubMed ID: 19332974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The danger of imperfect regulation: OxyContin use in the United States and Canada.
    Lexchin J; Kohler JC
    Int J Risk Saf Med; 2011; 23(4):233-40. PubMed ID: 22156088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The OxyContin crisis: problematisation and responsibilisation strategies in addiction, pain, and general medicine journals.
    Whelan E; Asbridge M
    Int J Drug Policy; 2013 Sep; 24(5):402-11. PubMed ID: 23452867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioequivalence of oxycodone hydrochoride extended release tablets to marketed reference products OxyContin® in Canada and US.
    Gosai P; Ducharme MP; Godfrey AR; Freeman JC; Monif T; Kumar KS; Kumar S; Mudnaik R; Katikaneni P
    Int J Clin Pharmacol Ther; 2013 Nov; 51(11):895-907. PubMed ID: 23673291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Evaluation of the Effect of the OxyContin Reformulation on Unintentional Fatal and Nonfatal Overdose.
    Beachler DC; Hall K; Garg R; Banerjee G; Li L; Boulanger L; Yuce H; Walker AM
    Clin J Pain; 2022 Jun; 38(6):396-404. PubMed ID: 35356897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protocol: changes in rates of opioid overdose and poisoning events in an integrated health system following the introduction of a formulation of OxyContin® with abuse-deterrent properties.
    Janoff SL; Perrin NA; Coplan PM; Chilcoat HD; Campbell CI; Green CA
    BMC Pharmacol Toxicol; 2016 May; 17(1):21. PubMed ID: 27177423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol.
    Degenhardt L; Larance B; Bruno R; Lintzeris N; Ali R; Farrell M
    Addiction; 2015 Feb; 110(2):226-37. PubMed ID: 25358480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OxyContin in Ontario: the multiple materialities of prescription painkillers.
    King S
    Int J Drug Policy; 2014 May; 25(3):486-93. PubMed ID: 24612641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Online Conversation Monitoring to Understand the Opioid Epidemic: Epidemiological Surveillance Study.
    Black JC; Margolin ZR; Olson RA; Dart RC
    JMIR Public Health Surveill; 2020 Jun; 6(2):e17073. PubMed ID: 32597786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of abuse-deterrent OxyContin on prescription opioid utilization.
    Hwang CS; Chang HY; Alexander GC
    Pharmacoepidemiol Drug Saf; 2015 Feb; 24(2):197-204. PubMed ID: 25393216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacy-related theft of controlled substances: RxPATROL® findings.
    Erensen JG; Haddox JD; Attre MS; Bauza LN
    J Opioid Manag; 2018; 14(5):373-380. PubMed ID: 30387860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Seeking drug treatment for OxyContin abuse: a chart review of consecutive admissions to a substance abuse treatment facility in Kentucky.
    Hays L; Kirsh KL; Passik SD
    J Natl Compr Canc Netw; 2003 Jul; 1(3):423-8. PubMed ID: 19761073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The promotion and marketing of oxycontin: commercial triumph, public health tragedy.
    Van Zee A
    Am J Public Health; 2009 Feb; 99(2):221-7. PubMed ID: 18799767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prescription Opioid Misuse Index: a brief questionnaire to assess misuse.
    Knisely JS; Wunsch MJ; Cropsey KL; Campbell ED
    J Subst Abuse Treat; 2008 Dec; 35(4):380-6. PubMed ID: 18657935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.